Skip to main content

Milestone 1.A

Enable precision medicine research by supporting deep and longitudinal molecular endophenotyping of existing and new at-risk cohorts as well cohorts and/or individuals who resist disease despite high genetic risk (e.g. Down Syndrome, ApoE 4 homozygous, FAD mutation carriers). Ensure that these efforts include and prioritize molecular profiling in cohorts from special populations and patients with atypical AD and ADRD (Down Syndrome, early- and late-onset familial AD, early-onset non-autosomal dominant AD), ethnic minorities and other under-represented groups.


Success Criteria

Initiate at least 6 research programs to support:

  • Longitudinal as well as postmortem collection and rapid distribution of biosamples from brain and peripheral tissues in existing and newly launched cohorts across diverse population groups.
  • Generation of high-quality, multi-omic data (genomic, epigenomic, proteomic, metabolomics, microbiome) as a public/community resource to maximize data accessibility and usability for downstream analyses.
  • Collection of non-traditional data modalities to complement the rich phenotypic clinical and molecular data, using wearable sensors and mobile health technologies.
  • High-quality data curation, annotation and data storage/big data infrastructure to ensure that the data are made broadly and rapidly available as a public resource according to FAIR data standards.


Research Implementation Area
Population Studies and Precision Medicine
Timeline
2016–2023
Status
In Progress

Accomplishments/Implementation Activities

Funding Initiatives

Research Programs and Resources

Research Highlights

Relevant Recommendations